# Vedanta Biosciences

> Vedanta Biosciences is a late clinical-stage biopharmaceutical company in Cambridge, Massachusetts (19 Blackstone Street), founded by PureTech Health with a group of scientific co-founders who pioneered the modern understanding of cross-talk between the human microbiome and the immune system. It develops oral Live Biotherapeutic Products built from rationally defined consortia of human commensal bacteria grown from pure clonal cell banks — not from donor stool — for gastrointestinal and immune-mediated disease. It is led by founder and CEO Bernat Olle, Ph.D.

Vedanta Biosciences is a therapeutics developer, not a software vendor. As of 2026-08-02 it publishes **no public API, no developer portal, no API documentation, no SDK and no machine-readable API contract**. Its web presence is a WordPress corporate and clinical-programs site. Do not assume or invent an `api.vedantabio.com`, `docs.vedantabio.com` or `developer.vedantabio.com` endpoint — none of those hosts resolve. `/.well-known/agent-card.json`, `/.well-known/agent.json`, `/.well-known/security.txt`, `/llms.txt`, `/openapi.json` and `/swagger.json` all return 404 on both `vedantabio.com` and `www.vedantabio.com`.

This file was generated by the API Evangelist enrichment pipeline; it is not published by Vedanta Biosciences.

## Company

- [Vedanta Biosciences](https://www.vedantabio.com/): company website
- [Mission](https://www.vedantabio.com/who-we-are/mission/): "Advancing the treatment of gastrointestinal diseases using defined bacterial consortia"
- [Leadership](https://www.vedantabio.com/who-we-are/leadership/): executive team
- [Team](https://www.vedantabio.com/who-we-are/team/)
- [Board of Directors](https://www.vedantabio.com/who-we-are/board-of-directors/)
- [Scientific Advisory Board](https://www.vedantabio.com/who-we-are/scientific-advisory-board/)
- [Partnerships](https://www.vedantabio.com/who-we-are/partnerships/): BARDA (reimbursement of up to $114.2M for VE303, subject to milestones) and CARB-X (research grants for VE303 and VE707)
- [Crunchbase](https://www.crunchbase.com/organization/vedanta-biosciences): funding and company profile
- [Forge Global](https://forgeglobal.com/vedanta-biosciences_stock/): private-company secondary-market listing

## Science and platform

- [Defined bacterial consortia](https://www.vedantabio.com/our-science/defined-bacterial-consortia/): the core scientific approach
- [Product engine](https://www.vedantabio.com/our-science/product-engine/): discovery-through-development platform
- [Manufacturing](https://www.vedantabio.com/our-science/manufacturing/): manufacture of live organisms from pure clonal cell banks
- [Intellectual property](https://www.vedantabio.com/our-science/intellectual-property/)
- [Publications](https://www.vedantabio.com/our-science/publications/): peer-reviewed literature

## Pipeline

- [Pipeline](https://www.vedantabio.com/pipeline-programs/pipeline/): full program list
- [VE303](https://www.vedantabio.com/pipeline-programs/ve303/): lead program, an eight-strain defined bacterial consortium in the global Phase 3 RESTORATiVE303 registrational study for prevention of recurrent *Clostridioides difficile* infection; Phase 2 reported a greater than 80% reduction in the odds of CDI recurrence versus placebo
- [VE707](https://www.vedantabio.com/pipeline-programs/ve707/): prevention of multidrug-resistant organism infections
- VE202: in development for inflammatory bowel disease

## Patients and clinical

- [How it works](https://www.vedantabio.com/commitment-to-patients/how-it-works/)
- [C. difficile infection](https://www.vedantabio.com/commitment-to-patients/c-difficile-infection/)
- [RESTORATiVE303 study](https://www.vedantabio.com/commitment-to-patients/restorative303/)
- [Expanded access policy](https://www.vedantabio.com/commitment-to-patients/expanded-access-policy/)

## News

- [Press releases](https://www.vedantabio.com/our-science/press-releases/)
- [Press release RSS](https://www.vedantabio.com/our-science/press-releases/feed/)
- [Site RSS](https://www.vedantabio.com/feed/)

## Code

Vedanta operates a GitHub organization, but it publishes research code rather than client libraries — there is no SDK.

- [github.com/vedantabio](https://github.com/vedantabio): organization (3 public repositories)
- [VE303-Ph1-paper](https://github.com/vedantabio/VE303-Ph1-paper): R analysis code for the Cell Host & Microbe VE303 Phase 1a/1b manuscript
- [VE303-Ph2-paper](https://github.com/vedantabio/VE303-Ph2-paper): R analysis code accompanying the Phase 2 VE303 results

## Contact and social

- [Contact](https://www.vedantabio.com/contact/) — 19 Blackstone Street, Cambridge, MA 02139, USA; +1 857-706-1427
- [Careers / open positions](https://www.vedantabio.com/who-we-are/open-positions/)
- [LinkedIn](https://www.linkedin.com/company/vedanta-biosciences-inc-)
- [X](https://x.com/vedantabio)

## Legal

- [Terms and conditions](https://www.vedantabio.com/terms-and-conditions/)
- [Privacy policy](https://www.vedantabio.com/privacy-policy/)